Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
MET
brain astasis
met
non-small cell lung cancer
tepotinib
Journal
Thoracic cancer
ISSN: 1759-7714
Titre abrégé: Thorac Cancer
Pays: Singapore
ID NLM: 101531441
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
25
12
2020
revised:
13
01
2021
accepted:
13
01
2021
pubmed:
4
2
2021
medline:
20
11
2021
entrez:
3
2
2021
Statut:
ppublish
Résumé
Mesenchymal-epithelial transition (MET) pathway activation is associated with the mechanisms that influence properties affecting cancer cell survival and invasiveness. The MET exon 14 skipping mutation (METex14del) is found in 2%-3% of patients with non-small cell lung cancer (NSCLC). Previous studies reported that NSCLC patients harboring a METex14del responded well to MET-tyrosine kinase inhibitors (TKIs), including tepotinib. Tepotinib is a highly selective, once-daily oral MET inhibitor that has shown promising clinical activity in patients with NSCLC with METex14del. The Food and Drug Administration accepted a new drug application for tepotinib as a treatment for patients with metastatic NSCLC harboring METex14del in February 2021 [Correction added on 5 March 2021, after first online publication: the FDA approval date for tepotinib has been corrected from 'September 2019' to 'February 2021'.]. However, in the previous clinical trials involving MET-TKIs, only patients with stable central nervous system metastases were eligible, and those with untreated symptomatic brain metastases (BMs) were excluded. Therefore, the efficacy and safety of MET-TKIs in that population remains unknown. We herein report a case of dramatic intracranial response to tepotinib in a patient with symptomatic BMs from lung adenocarcinoma harboring METex14del. In the current report, the symptoms derived from multiple BMs (headache and loss of appetite) rapidly disappeared, and brain magnetic resonance imaging (MRI) examination showed that all the lesions were too small to measure only 23 days after the commencement of tepotinib. For NSCLC patients with multiple BMs, whole-brain irradiation is a standard-of-care therapy, but its adverse effects on neurocognition are concerning. Tepotinib might therefore be a therapeutic option for NSCLC patients with symptomatic multiple BMs harboring METex14del.
Identifiants
pubmed: 33533182
doi: 10.1111/1759-7714.13871
pmc: PMC7952779
doi:
Substances chimiques
Piperidines
0
Pyridazines
0
Pyrimidines
0
tepotinib
1IJV77EI07
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
978-980Subventions
Organisme : Japanese Foundation for Multidisciplinary Treatment of Cancer
Informations de copyright
© 2021 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Références
Arch Toxicol. 2015 Aug;89(8):1227-40
pubmed: 25983263
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Curr Treat Options Oncol. 2020 Apr 18;21(4):33
pubmed: 32306194
J Thorac Oncol. 2017 Jan;12(1):152-156
pubmed: 27693535
Lancet Respir Med. 2017 Sep;5(9):707-716
pubmed: 28734822
J Natl Compr Canc Netw. 2012 Oct 1;10(10):1236-71
pubmed: 23054877
Ann Oncol. 2019 Dec 1;30(12):1985-1991
pubmed: 31584608
J Thorac Oncol. 2017 Jan;12(1):15-26
pubmed: 27794501
J Thorac Oncol. 2019 Jul;14(7):e137-e139
pubmed: 31055074
Thorac Cancer. 2021 Mar;12(6):978-980
pubmed: 33533182